Eli Lilly Zepbound Results

Order byBest matchMost fresh

Zepbound beats Wegovy for weight loss

Digest more

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

Zepbound achieved an average weight reduction of 20.2% compared to 13.7% with Wegovy after 72 weeks, it said.

· 1d · on MSN

· 2d · on MSN

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

· 1d · on MSN

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 1d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.

KDFW1d

Zepbound vs. Wegovy: Here's which weight loss drug worked best in first trial

People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s Wegovy. According to a study funded by Eli Lilly, the trial revealed that participants taking tirzepatide, the drug sold as Zepbound ...

12don MSN

Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell roughly 10% on investor worries that the move could blunt its sales momentum.

12d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.